Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307636 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4307637 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL31250397 | 0.79 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28595831 | 0.79 | RPLP1 (0.40) | SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL28597584 | 0.79 | RPLP1 (0.40) | SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL28628251 | 0.79 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28922139 | 0.79 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28621320 | 0.78 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28616422 | 0.78 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28517055 | 0.78 | SLC6A4 (0.35) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112292380-A | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2021-01-29 | — | — | CN | disclosed |